Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,773 across all filing types
Latest filing 2024-01-18 Director's Dealing
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec SE: Dr. Cord Dohrmann, Exercise against Cash Settlement (Share Performance Plan)
Director's Dealing Classification · 1% confidence The document explicitly states 'Directors’ Dealings' in the title and contains a section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details a transaction involving Dr. Cord Dohrmann, a Member of the managing body, regarding the exercise of shares under a Share Performance Plan. This content directly matches the definition for Director's Dealing.
2024-01-18 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership ('Notification of Major Holdings') by a legal entity (T. Rowe Price International Funds, Inc.) in Evotec SE, referencing specific German securities law articles (WpHG). This directly corresponds to the definition of reporting changes in significant share ownership thresholds, which aligns best with the Major Shareholding Notification category (MRQ). Although it is a regulatory announcement disseminated via EQS, the specific content is about major holdings, making MRQ more precise than the general RNS fallback.
2024-01-16 English
Evotec and Crohn s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies
Environmental & Social Information Classification · 1% confidence The document is a news release dated January 10, 2024, announcing a collaboration between Evotec SE and the Crohn’s & Colitis Foundation regarding drug discovery for IBD therapies. It is structured as a press release, containing key highlights, quotes, and boilerplate information about the involved entities. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it is a general corporate announcement disseminated via EQS News, and it doesn't fit into specific categories like M&A (TAR), Director's Dealing (DIRS), or Capital Changes (CAP), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings), as it serves as a broad corporate disclosure.
2024-01-10 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German securities law (WpHG). It details changes in the percentage of voting rights held by a specific entity (T. Rowe Price International Funds, Inc.) in Evotec SE, crossing a threshold on 04 Jan 2024. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2024-01-09 English
Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
Regulatory Filings Classification · 1% confidence The document is a news release dated January 8, 2024, announcing a specific business development: progress in a strategic neuroscience partnership between Evotec SE and Bristol Myers Squibb, which resulted in a US$ 25M payment to Evotec. It is not a full annual report (10-K), an interim report (IR), an earnings release (ER) detailing period financials, or a formal proxy/governance document. It is a specific corporate update regarding a partnership milestone. Since it is a general corporate announcement disseminated via EQS News, and it doesn't fit the specific categories like M&A (TAR), Capital (CAP), or Director's Dealing (DIRS), the most appropriate general category for a significant, non-financial-result-focused corporate update that isn't a standard regulatory filing like a 10-K or IR is the general Regulatory Filings category (RNS), as it serves as a broad announcement mechanism for material, non-standard news. However, given the content is a specific business/scientific update rather than a general regulatory filing, and it is not a presentation (IP) or a management discussion (MDA), RNS is the best fit among the available options for a material corporate news item that isn't covered by a more specific code.
2024-01-08 English
Company Presentation January 2024 (English)
Investor Presentation Classification · 1% confidence The document text is clearly structured as a "General company presentation" containing slides, disclaimers, forward-looking statements, an index/table of contents (PanOmics, iPSCs, Just Evotec Biologics, Financials), strategic overviews, pipeline status as of September 30, 2023, and discussions on technology convergence (A.I./ML). This format, content, and visual style are characteristic of an Investor Presentation (IP) used to communicate strategy, performance highlights, and pipeline progress to investors, rather than a formal regulatory filing like a 10-K or an Earnings Release (ER) which focuses strictly on financial results. The document is comprehensive and detailed, ruling out a simple Report Publication Announcement (RPA).
2024-01-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.